UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: April 18, 2011
(Date of earliest event reported)
SciClone Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 0-19825 | | 94-3116852 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
| |
950 Tower Lane, Suite 900 Foster City, CA | | 94404 |
| (Address of principal executive offices) | | (Zip Code) |
(650) 358-3456
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
On April 19, 2011, SciClone Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) reporting the completion of its acquisition of NovaMed Pharmaceuticals, Inc. (“NovaMed”). This Amendment No. 1 to the Initial Form 8-K amends and supplements the Initial Form 8-K to include financial statements required by Items 9.01(a) of Form 8-K to be filed by amendment no later than 71 calendar days after the date that the Initial Form 8-K was required to be filed with the Securities and Exchange Commission.
Item 9.01 Financial Statements and Exhibits.
| (a) | Financial Statements of Businesses Acquired. |
The audited consolidated balance sheets of NovaMed and its subsidiary as of December 31, 2010 and 2009, and the related consolidated statements of operations and cash flows for the years ended December 31, 2010 and 2009 are being filed as Exhibit 99.1 to this Current Report on Form 8-K/A.
| | |
Number | | Description |
| |
| 23.1 | | Consent of PricewaterhouseCoopers Zhong Tian CPAs Limited Company |
| |
| 99.1 | | Audited consolidated balance sheets of NovaMed and its subsidiary as of December 31, 2010 and 2009, and the related consolidated statements of operations and cash flows for the years ended December 31, 2010 and 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| Dated: July 5, 2011 | | | | SCICLONE PHARMACEUTICALS, INC. |
| | | |
| | | | By: | | /S/ GARY S. TITUS |
| | | | | | Gary S. Titus Chief Financial Officer and Senior Vice President, Finance |
Exhibit Index
| | |
Exhibit No. | | Description |
| |
| 23.1 | | Consent of PricewaterhouseCoopers Zhong Tian CPAs Limited Company |
| |
| 99.1 | | Audited consolidated balance sheets of NovaMed and subsidiary as of December 31, 2010 and 2009, and the related consolidated statements of operations and cash flows for the years ended December 31, 2010 and 2009 |
